MicroRNAs as therapeutic targets for lung cancer

Bibliography

• Cho WC. Role of miRNAs in lung cancer. Expert Rev Mol Diagn 2009;9:773-6
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42:1273-81
   PubMed Web of Science ®Google Scholar
• Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 2009;45:2197-206
   PubMed Web of Science ®Google Scholar
• Liu X, Sempere LF, Ouyang H, MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-309
   PubMed Web of Science ®Google Scholar
• Ebi H, Sato T, Sugito N, Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009;28:3371-9
   PubMed Web of Science ®Google Scholar
• Duan W, Gao L, Wu X, MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. Int J Cancer 2010;127:313-20
   PubMed Web of Science ®Google Scholar
• Incoronato M, Garofalo M, Urso L, MiR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 2010;70:3638-46
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs in cancer – from research to therapy. Biochim Biophys Acta Rev Cancer 2010;1805:209-17
   PubMed Web of Science ®Google Scholar
• Trang P, Medina PP, Wiggins JF, Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010;29:1580-7
   PubMed Web of Science ®Google Scholar
• Wiggins JF, Ruffino L, Kelnar K, Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923-30
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu X, Zhang X, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650-6
   PubMed Web of Science ®Google Scholar
• Garofalo M, Di Leva G, Romano G, MiR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509
   PubMed Web of Science ®Google Scholar
• Muniyappa MK, Dowling P, Henry M, MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. Eur J Cancer 2009;45:3104-18
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Lin W, Creighton CJ, Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009;23:2140-51
   PubMed Web of Science ®Google Scholar
• Ma L, Reinhardt F, Pan E, Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010;28:341-7
   PubMed Web of Science ®Google Scholar
• Sarkar FH, Li Y, Wang Z, Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010;13:57-66
   PubMed Web of Science ®Google Scholar
• Guo L, Liu Y, Bai Y, Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010;46:1692-702
   PubMed Web of Science ®Google Scholar
• Zhu W, Shan X, Wang T, MiR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, doi:10.1002/ijc.25260
   Google Scholar
• Galluzzi L, Morselli E, Vitale I, MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70:1793-803
   PubMed Web of Science ®Google Scholar
• Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 2010;76:5-8
   PubMed Web of Science ®Google Scholar
• Cho WC. Conquering cancer through discovery research. IUBMB Life 2010;62:645-50
   Web of Science ®Google Scholar
• Young DD, Connelly CM, Grohmann C, Deiters A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 2010;132:7976-81
   PubMed Web of Science ®Google Scholar
• Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4:721-6
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aseguinolaza G, Prieto J. Durable correction of inherited metabolic liver disorders requires preventing transgene off-targeting from gene therapy vectors: the value of microRNAs. Gastroenterology 2010;139:726-9
   PubMed Web of Science ®Google Scholar
• Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010;11:457-60
   PubMed Web of Science ®Google Scholar
• Rossbach M. Small non-coding RNAs as novel therapeutics. Curr Mol Med 2010;10:361-8
   PubMed Web of Science ®Google Scholar
• Seto AG. The road toward microRNA therapeutics. Int J Biochem Cell Biol 2010;42:1298-305
   PubMed Web of Science ®Google Scholar
• Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta Mol Cell Res 2010;1803:1231-43
   PubMed Web of Science ®Google Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs in cancer translational research. Springer, New York; In press
   Google Scholar